Post by Andrew Chen

Name: Beyond Hepatitis B: Amoytop Biotech's Expanding Pipeline In today's video, we take a closer look at
Uploaded: 2026-07-14T09:46:28.124Z
Channel: Andrew Chen
Description: Beyond Hepatitis B: Amoytop Biotech's Expanding Pipeline In today's video, we take a closer look at Amoytop Biotech, a Chinese biopharma company known for its work in hepatitis B. Beyond its establi

Beyond Hepatitis B: Amoytop Biotech's Expanding Pipeline In today's video, we take a closer look at Amoytop Biotech, a Chinese biopharma company known for its work in hepatitis B. Beyond its established products, the company is continuing to invest in innovative therapies across multiple therapeutic areas, reflecting a broader trend in China's rapidly evolving biopharmaceutical industry. 💡 For educational and industry news purposes only. Not medical advice. #HepatitisB #DengYuePharmacy #AmoytopBiotech #PegBeron #PeginterferonAlfa2b #Inpegsomatropin #Yipeisheng #Pevifoscorvir #ALG000184 #ChinaPharma #ChineseBiopharma #InnovativeDrugs #MedicalResearch #PharmaceuticalDistributor #ChinaPharmacy #OnlinePharmacy #GlobalPharma #DengYueMed 标题：不止乙肝！中国龙头特宝生物迈入新赛道（Beyond Hepatitis B! China's Biopharma Leader Amoytop Expands Into New Therapeutic Areas）提到特宝生物（Amoytop Biotech），很多人首先想到的是乙肝创新药派格宾。作为全球首个Y型40kD聚乙二醇干扰素α-2b注射液，它是中国慢性乙肝治疗的重要创新药之一。如今，特宝生物正加速转型。除了推出长效生长激素益佩生，还布局了Pevifoscorvir sodium（ALG-000184）、ACT201、ACT560等创新管线，并将研发拓展至代谢疾病、自身免疫、肿瘤和AAV基因治疗等领域。从乙肝龙头到多赛道创新，特宝生物正在开启新的增长阶段。

Video Content